Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Hurley Medical Center
mi
from
Flint, MI
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Hurley Medical Center
mi
from
Flint, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Genesys Regional Medical Center-West Flint Campus
mi
from
Flint, MI
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Genesys Regional Medical Center-West Flint Campus
mi
from
Flint, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Genesys Regional Medical Center
mi
from
Grand Blanc, MI
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Genesys Regional Medical Center
mi
from
Grand Blanc, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Allegiance Health
mi
from
Jackson, MI
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Allegiance Health
mi
from
Jackson, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Sparrow Hospital
mi
from
Lansing, MI
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Sparrow Hospital
mi
from
Lansing, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Saint Mary Mercy Hospital
mi
from
Livonia, MI
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Saint Mary Mercy Hospital
mi
from
Livonia, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Saint Joseph Mercy Oakland
mi
from
Pontiac, MI
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Saint Joseph Mercy Oakland
mi
from
Pontiac, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Saint Joseph Mercy Port Huron
mi
from
Port Huron, MI
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Saint Joseph Mercy Port Huron
mi
from
Port Huron, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Saint Mary's of Michigan
mi
from
Saginaw, MI
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Saint Mary's of Michigan
mi
from
Saginaw, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Saint John Macomb-Oakland Hospital
mi
from
Warren, MI
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Saint John Macomb-Oakland Hospital
mi
from
Warren, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Cancer Research for the Ozarks NCORP
mi
from
Springfield, MO
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Cancer Research for the Ozarks NCORP
mi
from
Springfield, MO
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Cox Medical Center South
mi
from
Springfield, MO
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Cox Medical Center South
mi
from
Springfield, MO
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Case Western Reserve Univ
mi
from
Cleveland, OH
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
MetroHealth Med Ctr
mi
from
Cleveland, OH
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Riverside Methodist Hospital
mi
from
Columbus, OH
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Abington Memorial Hospital
mi
from
Abington, PA
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/4/2016
Women and Infants Hospital
mi
from
Providence, RI
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/4/2016
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer
Non-Small-Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer: Demographics, Treatment and Outcome Characteristics of Patient Cases in a Community-Based Setting
Status: Enrolling
Updated:  3/4/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer
Non-Small-Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer: Demographics, Treatment and Outcome Characteristics of Patient Cases in a Community-Based Setting
Status: Enrolling
Updated: 3/4/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Intensive Diet and Exercise or Standard of Care in Improving Physical Function and Quality of Life in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
The Intensive Diet and Exercise Adherence Trial - Pilot (IDEA-P): A Feasibility Study of a Lifestyle Intervention in Men Undergoing Androgen Deprivation Therapy
Status: Enrolling
Updated:  3/4/2016
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Intensive Diet and Exercise or Standard of Care in Improving Physical Function and Quality of Life in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
The Intensive Diet and Exercise Adherence Trial - Pilot (IDEA-P): A Feasibility Study of a Lifestyle Intervention in Men Undergoing Androgen Deprivation Therapy
Status: Enrolling
Updated: 3/4/2016
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Genetic Biomarkers in Tissue Samples From Patients With Osteosarcoma
Observational - Gene Discovery in Osteosarcoma
Status: Enrolling
Updated:  3/4/2016
Children's Oncology Group
mi
from
Monrovia, CA
Genetic Biomarkers in Tissue Samples From Patients With Osteosarcoma
Observational - Gene Discovery in Osteosarcoma
Status: Enrolling
Updated: 3/4/2016
Children's Oncology Group
mi
from
Monrovia, CA
Click here to add this to my saved trials
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making
Status: Enrolling
Updated:  3/7/2016
VA Medical Center, San Francisco
mi
from
San Francisco, CA
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making
Status: Enrolling
Updated: 3/7/2016
VA Medical Center, San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making
Status: Enrolling
Updated:  3/7/2016
VA Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making
Status: Enrolling
Updated: 3/7/2016
VA Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making
Status: Enrolling
Updated:  3/7/2016
VA Medical Center
mi
from
Durham, NC
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making
Status: Enrolling
Updated: 3/7/2016
VA Medical Center
mi
from
Durham, NC
Click here to add this to my saved trials
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making
Status: Enrolling
Updated:  3/7/2016
Center for Health Equity Research and Promotion
mi
from
Pittsburgh, PA
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer
Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making
Status: Enrolling
Updated: 3/7/2016
Center for Health Equity Research and Promotion
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated:  3/7/2016
1199.14.1091 Boehringer Ingelheim Investigational Site
mi
from
Fountain Valley, CA
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated: 3/7/2016
1199.14.1091 Boehringer Ingelheim Investigational Site
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated:  3/7/2016
1199.14.1164 Boehringer Ingelheim Investigational Site
mi
from
Fullerton, CA
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated: 3/7/2016
1199.14.1164 Boehringer Ingelheim Investigational Site
mi
from
Fullerton, CA
Click here to add this to my saved trials
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated:  3/7/2016
1199.14.1181 Boehringer Ingelheim Investigational Site
mi
from
Long Beach, CA
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated: 3/7/2016
1199.14.1181 Boehringer Ingelheim Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated:  3/7/2016
1199.14.1080 Boehringer Ingelheim Investigational Site
mi
from
Meriden, CT
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated: 3/7/2016
1199.14.1080 Boehringer Ingelheim Investigational Site
mi
from
Meriden, CT
Click here to add this to my saved trials
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated:  3/7/2016
1199.14.1194 Boehringer Ingelheim Investigational Site
mi
from
Boynton Beach, FL
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated: 3/7/2016
1199.14.1194 Boehringer Ingelheim Investigational Site
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated:  3/7/2016
Boehringer Ingelheim Investigational Site
mi
from
Jacksonville, FL
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated: 3/7/2016
Boehringer Ingelheim Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated:  3/7/2016
Boehringer Ingelheim Investigational Site
mi
from
Miami, FL
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated: 3/7/2016
Boehringer Ingelheim Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated:  3/7/2016
1199.14.1057 Boehringer Ingelheim Investigational Site
mi
from
New Port Richey, FL
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated: 3/7/2016
1199.14.1057 Boehringer Ingelheim Investigational Site
mi
from
New Port Richey, FL
Click here to add this to my saved trials
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated:  3/7/2016
1199.14.1055 Boehringer Ingelheim Investigational Site
mi
from
Stuart, FL
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated: 3/7/2016
1199.14.1055 Boehringer Ingelheim Investigational Site
mi
from
Stuart, FL
Click here to add this to my saved trials
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated:  3/7/2016
1199.14.1188 Boehringer Ingelheim Investigational Site
mi
from
Galesburg, IL
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated: 3/7/2016
1199.14.1188 Boehringer Ingelheim Investigational Site
mi
from
Galesburg, IL
Click here to add this to my saved trials
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated:  3/7/2016
1199.14.1261 Boehringer Ingelheim Investigational Site
mi
from
Skokie, IL
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated: 3/7/2016
1199.14.1261 Boehringer Ingelheim Investigational Site
mi
from
Skokie, IL
Click here to add this to my saved trials
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated:  3/7/2016
1199.14.1152 Boehringer Ingelheim Investigational Site
mi
from
Indianapolis, IN
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated: 3/7/2016
1199.14.1152 Boehringer Ingelheim Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated:  3/7/2016
1199.14.1058 Boehringer Ingelheim Investigational Site
mi
from
New Albany, IN
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated: 3/7/2016
1199.14.1058 Boehringer Ingelheim Investigational Site
mi
from
New Albany, IN
Click here to add this to my saved trials
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated:  3/7/2016
1199.14.1079 Boehringer Ingelheim Investigational Site
mi
from
Ashland, KY
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated: 3/7/2016
1199.14.1079 Boehringer Ingelheim Investigational Site
mi
from
Ashland, KY
Click here to add this to my saved trials
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated:  3/7/2016
1199.14.1172 Boehringer Ingelheim Investigational Site
mi
from
Louisville, KY
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated: 3/7/2016
1199.14.1172 Boehringer Ingelheim Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated:  3/7/2016
1199.14.1051 Boehringer Ingelheim Investigational Site
mi
from
Burlington, MA
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated: 3/7/2016
1199.14.1051 Boehringer Ingelheim Investigational Site
mi
from
Burlington, MA
Click here to add this to my saved trials
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated:  3/7/2016
1199.14.1182 Boehringer Ingelheim Investigational Site
mi
from
Springfield, MA
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated: 3/7/2016
1199.14.1182 Boehringer Ingelheim Investigational Site
mi
from
Springfield, MA
Click here to add this to my saved trials
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated:  3/7/2016
1199.14.1086 Boehringer Ingelheim Investigational Site
mi
from
Grand Island, NE
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status: Enrolling
Updated: 3/7/2016
1199.14.1086 Boehringer Ingelheim Investigational Site
mi
from
Grand Island, NE
Click here to add this to my saved trials